Famotidine

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Reflux

Conditions

Gastroesophageal Reflux

Trial Timeline

Sep 1, 2005 → —

About Famotidine

Famotidine is a phase 2/3 stage product being developed by Astellas Pharma for Gastroesophageal Reflux. The current trial status is completed. This product is registered under clinical trial identifier NCT00141960. Target conditions include Gastroesophageal Reflux.

What happened to similar drugs?

18 of 20 similar drugs in Gastroesophageal Reflux were approved

Approved (18) Terminated (2) Active (2)
Placebo + CisaprideJohnson & JohnsonApproved
ApatinibTabletsJiangsu Hengrui MedicineApproved
EsomeprazoleAstraZenecaApproved
EsomeprazoleAstraZenecaApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00141960Phase 2/3Completed